Olivier Hermine
Olivier Hermine, MD, PhD is an expert in Hematology at Hôpital Necker-Enfants Malades (France). As of October 2026, ScienceLeadR ranks Olivier Hermine in the top 1% of experts worldwide for Lymphoma, Lymphoproliferative Disorders and Anemia. Olivier Hermine has authored 1,588 publications, the most recent in 2026, and is an investigator in 60 clinical trials, 9 of them ongoing. SLR score: 7,265 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Immunology - Oncology - Transplantation
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1991 - 2026
Number : 1588
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Anti-thymocyte globulin triggers TNF-dependent cell death in T-cell acute lymphoblastic leukemia. PMID 42901909 — thymocytes, cells, precursor cell lymphoblastic leukemia-lymphoma, leukemia, therapeutics, t-lymphocytes, globulins, cell death | Nat Commun | 2026 | 0 |
| The Proteasome Safeguards Red Blood Cell Integrity During Storage and After Transfusion. PMID 42792185 — cells, erythrocytes, blood, aging, cellular senescence, oxidative stress, proteasome endopeptidase complex, blood cells | Antioxidants (Basel) | 2026 | 0 |
| Metabolic profiling of CAR T-cells in patients reveals a shift toward amino acid-supported OXPHOS and informs transporter engineering. PMID 42780275 — cells, microscopy, electron, scanning transmission, amino acids, car-t cell | Res Sq | 2026 | 0 |
| When precaution outlasts evidence: reconsidering blood collection in French Guiana. PMID 42668472 — blood | Lancet Reg Health Am | 2026 | 0 |
| Hospital at Home for BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A Multicenter Real-World Feasibility and Safety Study. PMID 42660762 — disease-free survival, safety, progression-free survival, antibodies, lymphoma, multiple myeloma, therapeutics, antibodies, bispecific, infections | Clin Lymphoma Myeloma Leuk | 2026 | 0 |
Clinical Studies 60
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 6
Ongoing Clinical Trials
9 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| CAR T cell treatment for untreated high risk MANtle Cell Lymphoma 2022-502405-15-01 — cells, lymphoma, maintenance, rituximab, lymphoma, mantle-cell, therapeutics, t-lymphocytes, car-t cell | Phase 2 | Recruiting | 2024 |
| LUSPARA Luspatercept in patients affected with rare inherited anemias 2024-520200-26-00 — hemoglobins, anemia | Phase 2 | Recruiting | 2026 |
| A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator s Choice in Patients with Relapsed Refractory Mantle Cell Lymphoma 2023-503206-37-00 — cells, safety, lymphoma, rituximab, lymphoma, mantle-cell, therapeutics | Phase 3 | Recruiting | 2023 |
| Phase IIa Trial of Anti CD19 CAR T Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy NCT07493395 — skin, cells, sclerosis, pharmaceutical preparations, leukapheresis, drug therapy, receptors, antigen, lymph, receptors, chimeric antigen, therapeutics, immunosuppression therapy, infusions, intravenous, t-lymphocytes, scleroderma, systemic, chemotherapy, car-t cell | Phase 2 | Recruiting | 2026 |
| Luspatercept in Patients Affected With Rare Inherited Anemias NCT07331818 — injections, cells, erythrocytes, blood, powders, anemia, solutions, blood cells | Phase 2 | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map